2 months Vertex Pharmaceuticals (NASDAQ:VRTX) Given Buy Rating at HC Wainwright MarketBeat
HC Wainwright reissued a “buy” rating and issued a $600.00 price objective on shares of Vertex Pharmaceuticals in a research note on Monday.
Nasdaq 100 · Pharmaceuticals · Science · Vertex (VRTX)
X